William Brown, MD
Internal Medicine · Hampton, VANPI 1073715736
Payments from drug & device makers
Across 83 payments — averaging $74.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$4K
- Amgen$327
- Lilly USA, LLC$236
- AstraZeneca$211
- GSK$186
- Novo Nordisk$174
- plus $706 from 20 others
What the payments were for
- Speaking & faculty fees$3,02249%
- Travel & lodging$82313%
- Food & beverage$2,30937%
- Education$371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 7 | $4,351 |
| Amgen | 7 | $327 |
| Lilly USA, LLC | 8 | $236 |
| AstraZeneca | 12 | $211 |
| GSK | 5 | $186 |
| Novo Nordisk | 9 | $174 |
| Abbott | 6 | $110 |
| Insightec,inc | 2 | $90 |
| Sanofi Pasteur Inc. | 3 | $75 |
| Boehringer Ingelheim | 3 | $59 |
| Astellas Pharma US Inc | 2 | $43 |
| Novartis | 3 | $42 |
| Currax Pharmaceuticals LLC | 2 | $40 |
| AbbVie | 2 | $30 |
| Averitas Pharma Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Merck | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$4,269
- Repatha$246
- AREXVY$125
How this compares
$6,190 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $96,019 |
| OzempicSemaglutide | 58 | $60,773 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 55 | $43,698 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $36,666 |
| JanuviaSitagliptin Phosphate | 19 | $25,155 |
| JardianceEmpagliflozin | 13 | $21,561 |
| XareltoRivaroxaban | 18 | $16,504 |
| RayaldeeCalcifediol | 12 | $13,858 |
| FarxigaDapagliflozin Propanediol | 12 | $4,604 |
| Atorvastatin Calcium | 366 | $3,552 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $3,481 |
| SynthroidLevothyroxine Sodium | 38 | $2,858 |
| Levothyroxine Sodium | 148 | $2,628 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr, Janumet, Januvia | $15 | $105,519106 claims |
| PfizerEliquis | $13 | $96,019107 claims |
| Novo NordiskOzempic | $174 | $60,77358 claims |
| Boehringer IngelheimJardiance | $59 | $21,56113 claims |
| Johnson & JohnsonXarelto | $15 | $16,50418 claims |
| AstraZenecaFarxiga | $211 | $4,60412 claims |
| AbbVieSynthroid | $30 | $2,85838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Hampton
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.